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1. Introduction  
Rabies is a fatal viral infection that is most commonly spread to humans through the bite of 
an infected animal. The disease is an acute progressive encephalitis caused by highly 
neurotropic zoonotic viruses belonging to the Lyssavirus genus in the Rhabdoviridae family 
(Kuzmin, 2009). Of the twelve species of lyssaviruses, rabies virus (RABV) is the most 
important with respect to its impact on public health. RABV is distributed globally and 
found on all continents except Australia and Antarctica. In the United States, multiple RABV 
variants circulate in wild mammalian reservoir populations including raccoons, skunks, 
foxes, and bats. Rabies has the highest case fatality rate of any infectious disease and kills an 
estimated 55,000 people annually, primarily in developing countries within Africa and Asia 
(Knobel, 2005). However, rabies is a preventable disease. Postexposure prophylaxis (PEP) 
consisting of rabies immune globulin and rabies vaccine is successful in preventing the 
disease when administered promptly after an exposure to the virus has occurred. 
Additionally, vaccination of domestic animals against rabies and stray animal control 
programs greatly reduce the risk of RABV transmission to humans. Implementation of these 
measures in developed countries such as the United States has led to drastic declines in the 
incidence of human rabies. Despite this success, rabies remains a significant public health 
issue. Each year approximately 7,000 rabid animals are reported in the United States 
(Blanton, 2010). Up to 35,000 people annually are estimated to receive PEP due to exposures 
to suspect rabid animals (Christian, 2009). Given the high cost of rabies PEP, this represents 
a substantial economic burden as well. A clear understanding of the epidemiology of human 
rabies in the United States can help to manage these human exposures using the best 
available evidence. In this way, the risk of infection can be assessed more precisely and 
ensure rabies PEP is administered more judiciously. The identification of epidemiologic 
patterns can also be used to focus educational messages for human rabies prevention and 
thereby increase public awareness of rabies and the importance of seeking medical care after 
a potential exposure occurs. Furthermore, providing accurate descriptions of the clinical 
presentation of human rabies is essential in recognizing and diagnosing the disease in a 
timely fashion. Delayed or missed diagnoses place others at risk of exposure if appropriate 
infection control precautions are not instituted, exposures are not treated appropriately, or 
organs or tissues from an infected individual are used for transplantation (Houff, 1979; 
Javadi, 1996; Hellenbrand, 2005; Kusne, 2005; Srinivasan, 2005). An early diagnosis also 
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provides the patient with the opportunity for treatment and possible survival. Insights 
gained from each attempt at treatment further our understanding of the disease and add to 
the body of knowledge that can be applied to future cases. When rabies is ruled out, efforts 
can be focused on identifying more treatable causes of encephalitis. With these goals in 
mind, this review will describe the epidemiology of human rabies, examine the signs and 
symptoms of disease, and review the laboratory diagnostic testing and results for all 
reported human rabies cases in the United States between 1960 and 2010. 
2. Methods 
2.1 Case definition and data sources 
This review includes all cases of human rabies reported to the Centers for Disease Control 
and Prevention (CDC) that occurred within the United States and its territories between the 
years 1960–2010. These cases include both indigenous cases occurring in  United States 
nationals as well as imported cases in foreign nationals diagnosed and treated within the 
United States and it territories. All cases were confirmed using standard diagnostic 
laboratory tests performed by CDC or by a state laboratory and were reported by health 
authorities as part of ongoing national surveillance. The clinical and laboratory findings 
were taken from CDC’s Morbidity and Mortality Reports, published journal articles, and 
unpublished CDC notes. In addition, this review contains clinical data from patients with 
suspected rabies submitted to the CDC for laboratory diagnostic testing between the years 
2007–2010 for whom rabies was subsequently ruled out (non-rabies cases). 
2.2 Variable definitions 
Onset of illness was defined as either the first day of reported symptoms attributable to 
rabies or, when this date was unknown, the date when medical care was first sought prior to 
the confirmation of rabies. Signs and symptoms attributable to rabies included aerophobia, 
hydrophobia, paresthesia or localized pain, priapism or spontaneous ejaculation, dysphagia, 
localized weakness, fever, muscle spasm, hypersalivation, anxiety, hallucinations, 
autonomic instability, agitation or combativeness, nausea or vomiting, ataxia, anorexia, 
insomnia, seizures, confusion or delirium, malaise or fatigue, and headache. When a bite 
from a known species, laboratory RABV exposure, or transplantation of infected organs or 
tissue was reported the species of biting animal or type of exposure and the location of the 
exposure incident are indicated in the exposure history. Probable exposures where no 
known bite occurred but physical contact with an animal or close proximity to an animal 
was reported are also indicated. All other exposures were defined as “unknown.”  The 
RABV variant determined by antigenic or molecular typing also provides evidence of the 
likely source of infection and is particularly useful when no exposure history is known. The 
type of case was defined as indigenous if the bite incident occurred in the United States or 
its territories or if the RABV variant identified matched an indigenous source. Imported 
cases were defined by an exposure occurring outside of the United States or its territories or 
by identification of a RABV variant not found within the United States. The diagnosis of 
rabies was considered antemortem when samples were obtained specifically for rabies 
diagnostic testing before death or when the signs, symptoms, and clinical history were 
deemed sufficient by the clinicians involved to establish the diagnosis. 
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2.3 Statistical analysis 
Data analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, North 
Carolina). Data were summarized using descriptive statistics and comparisons between 
human rabies cases and cases of encephalopathy with negative rabies diagnostic testing were 
made using Chi-square or Fisher’s exact test. Some variables were dichotomized before 
statistical comparisons for determination of odds ratios (OR) and 95% confidence intervals 
(CI). Associations were considered statistically significant at p-values less than 0.05.  
2.4 Diagnostic laboratory testing 
2.4.1 Detection of antigen 
RABV antigens were detected using the direct fluorescent antibody (DFA) test of skin 
biopsy specimens, touch impressions of corneal epithelial cells, or fresh brain tissue as 
described (CDC, 2006). Skin biopsy specimens were taken from the nuchal area of the neck 
where viral antigens can be present in hair follicles containing cutaneous nerves, as 
described previously (Noah, 1998).  
2.4.2 Serology 
RABV antibody testing for cases reported before 1973 utilized the mouse neutralization test 
(Jackson, 2003). After 1973, serology was determined using the rapid fluorescent focus 
inhibition test (RFFIT) or the indirect fluorescence assay (IFA), as described previously 
(Noah, 1998). The RFFIT measures RABV neutralizing antibodies while the IFA detects 
serum reactive with RABV antigen in infected cell cultures. Antibodies in serum were 
considered diagnostic if there was no history of rabies immunization prior to sample 
collection. Antibodies in cerebrospinal fluid (CSF) were considered diagnostic regardless of 
rabies immunization history. 
2.4.3 Virus isolation 
RABV was isolated through intracerebral inoculation of suckling mice or by addition of 
suspensions of brain or saliva specimens to cultured mouse neuroblastoma cells, as 
described previously (Noah, 1998).  
2.4.4 RNA detection 
Viral nucleic acids were obtained using standard extraction procedures and reagents. 
Samples used for nucleic acid extraction included saliva, fresh brain, paraffin-embedded 
brain, and nuchal skin. Reverse transcription polymerase chain reaction (RT-PCR) was 
performed using primers targeting the sequence of the nucleoprotein gene. Standard 
dideoxynucleotide sequencing methods were utilized to determine the nucleotide sequences 
of all PCR products obtained, as described previously (Noah, 1998). 
2.4.5 Identification of rabies virus variants 
RABV variants were identified through antigenic and/or molecular typing. Antigenic 
typing uses a reference panel of monoclonal antibodies directed against the nucleoprotein to 
determine the variant of RABV isolates. Molecular typing methods identify the RABV 
variant by comparing the nucleotide sequence obtained by RT-PCR with a database of 
sequences from known reservoirs within the United States as well as foreign countries 
throughout the world. 
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Table 1. Human Rabies in the United States, 1960–2010 
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3. Results 
A total of 108 cases of human rabies were reported in the United States from 1960 through 
2010 (Table 1). One hundred and four cases (96%) died and 4 (4%) survived. Fifty-three 
cases were diagnosed antemortem while 55 cases were diagnosed postmortem. Fifty-one of 
the cases diagnosed antemortem had positive laboratory diagnostic test results with the 
remaining 2 cases diagnosed based on the signs, symptoms, and clinical history alone 
3.1 Demographic Information 
The median age of patients was 29 years and ranged from 2 to 82 years. Forty cases (37%) 
were less than 20 years of age and 20 (19%) were 60 years or older. Eighty-three cases (77%) 
were male and 25 (33%) were female. Cases were reported from 35 states and territories 
(Figure 1); California and Texas were the only states with more than 5 cases and reported 20 
cases (19%) and 19 cases (18%) respectively. Of the states not represented in this series, all 
had reported a case of human rabies within the last century with the exception of Hawaii, 
North Dakota, Wyoming and Vermont. Illness onset occurred in all months but was most 
likely to occur during the fall (August, September, and October) when compared to other 
seasons (P-value = 0.001). Similarly, definite exposures occurring within the United States 
were more frequent in fall and summer months though this observation was not statistically 
significant (P-value = 0.27).  
 
 
Fig. 1. Geographic Distribution of Human Rabies Cases in the United States, 1960–2010 
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3.2 Source of infection 
The majority of human rabies cases (78/108; 72%) resulted from exposures that occurred 
within the United States and its territories. However, exposures in 12 foreign countries were 
responsible for a total of 30 imported cases. Exposures in Mexico were the most common 
and accounted for 13 imported cases. Animals were linked epidemiologically to 98 cases 
(91%) either by exposure history or RABV variant typing. Transplantation of infected organs 
or tissue was responsible for 5 cases (5%) and exposure to a laboratory RABV was 
implicated in two cases (2%). In 3 cases (3%) there was no history of exposure and no RABV 
variant identified to suggest a likely source of infection. The animal species linked 
epidemiologically to human rabies were bats (48/98; 49%), dogs (37/98; 38%), skunks (5/98; 
5%), foxes (2/98; 2%), a cat (1/98; 1%), a bobcat (1/98; 1%), and a raccoon (1/98; 1%). The 
species responsible for infection was unclear in three cases in which the RABV variant 
identified did not match the exposure history; patient 24 reported a bite from a stray cat 
while a RABV variant associated with skunks was identified, patient 55 reported contact 
with a sick cow that later died while a RABV variant associated with bats was identified, 
and patient 101 had a history of exposure to a dog and a fox while the RABV variant 
identified was most closely related to viruses found in bats. These appear to have been 
spillover infection from a primary reservoir species to another animal. In all other cases 
where an animal exposure was reported the RABV variant identified matched the species of 
the exposing animal. 
3.3 Exposure history 
A definite history of exposure to RABV was reported in 54 cases; 47 reported an animal bite, 
2 involved exposures to laboratory RABV, and 5 had undergone transplantation of infected 
organs or tissue. A probable exposure was reported in 26 cases, 21 of which involved a 
probable exposure to a bat and 5 described a probable exposure to a dog. Of the 28 cases 
with an unknown exposure, a bat RABV variant was identified in 16 cases, a dog RABV 
variant was identified in 8 cases, and RABV variants associated with raccoons and skunks 
were identified in 1 case each. Among the definite exposures involving animal bites, 27 
cases were indigenous cases involving bites from 12 bats, 7 dogs, 4 skunks, 2 foxes, 1 cat, 
and 1 bobcat. Only 2 of the 20 imported cases involved a RABV variant not associated with a 
domestic animal species. Only 9 animals involved in exposures were available for diagnostic 
testing, though all tested positive for RABV antigen. With respect to seasonality, rabies cases 
associated with bats (either by exposure or by identification of a bat RABV variant) were 
more likely to have onset of illness during the fall when compared to all other cases 
excluding those acquired through transplantation (OR 3.30; 95% CI 1.45–7.54). Exposures to 
bats were also more likely to occur during fall months when compared to exposures to other 
animals (OR 16.50; 95% CI 1.83–148.61). 
3.4 Prophylaxis 
Sixteen patients received PEP prior to the onset of symptoms. All of these cases occurred 
prior to 1980 and before the introduction of modern cell culture vaccines. Only two cases 
completed the PEP regimen according to recommended guidelines and can be considered 
true failures. The failure of PEP to prevent disease in the remaining 14 patients was 
attributed to either a delay in administration (i.e. administered greater than 72 hours after 
exposure), receipt of too few doses of vaccine, or failure to administer rabies immune 
globulin. Two patients had received rabies vaccine prior to their exposure: patient 22 
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received four doses of an experimental rabies vaccine 13 years prior to illness onset, 
however subsequent serologic testing failed to detect antibodies in serum; patient 29 
received pre-exposure prophylaxis and regular booster doses with duck embryo vaccine 
and had a positive RABV antibody titer 6 months before exposure. Patient 22 died of his 
illness, while patient 29 survived. 
3.5 Clinical course 
Excluding cases acquired through laboratory exposures and tissue and organ 
transplantation, specific dates of definite and probable exposures reported for 28 cases were 
used to calculate a median incubation period of 41.5 days (range 8–701 days). Fifty patients 
had sought healthcare prior to admission with a median of one day (range 0–6 days) 
between illness onset and presentation for medical evaluation. Hospital admission dates 
were reported in 94 cases with a median of 4 days (range 0–16 days) from the onset of illness 
to hospital admission. Median time from onset of illness to admission to an intensive care 
unit (ICU) was also 4 days (range 1–13 days) in 14 cases reporting ICU admission date. 
Similarly, in 65 cases reporting the date of intubation the median time from onset of illness 
to intubation was 5 days (range 1–19 days). Time from onset of illness to development of 
fever was reported in 30 cases giving a median of 2 days (range 0–11 days); time from onset 
of illness to development of coma was reported in 33 cases giving a median of 7 days (range 
1–28 days). The median length of illness (defined as days from illness onset until death) was 
13.5 days (range 1–133 days).  
3.6 Comparison of rabies cases and non-rabies cases 
3.6.1 Demographics 
Data available from 108 confirmed human rabies cases and 144 encephalitis cases where 
rabies was ruled out by laboratory diagnostic testing were compared (Table 2). Rabies cases 
were older on average than non-rabies cases with a mean of 34.4 years (range 2–82 years) 
versus 30.7 years (range <1–78 years). However, this result was not statistically significant. 
Male gender was nearly 2 times more likely among rabies cases than non-rabies cases (P-
value 0.019). 
 
Variable 
Positive, N=108 
n (%) 
Negative, N=144 
n (%) 
Odds Ratio  
(95% CI*) 
P-value 
Mean age (range) 34.35 (2–82) 30.72 (<1–78)  0.173 
Aerophobia 10 (9.3%) 1 (0.7%) 14.59 (1.84–115.83) 0.001† 
Hydrophobia 36 (33.3%) 9 (6.3%) 7.50 (3.42–16.43) <0.001† 
Paresthesia or 
localized pain 
54 (50.0%) 21 (14.6%) 5.86 (3.22–10.64) <0.001† 
Priapism or 
spontaneous 
ejaculation 
4 (3.7%) 2 (1.4%) 2.73 (0.50–15.19) 0.41 
Dysphagia 53 (49.1%) 43 (29.9%) 2.26 (1.35–3.80) 0.003† 
Localized weakness 44 (40.7%) 34 (23.6%) 2.22 (1.29–3.83) 0.004† 
Male gender 83 (76.9%) 87 (62.6%) 1.98 (1.13–3.49) 0.019† 
Fever 90 (83.3%) 113 (78.5%) 1.37 (0.72–2.61) 0.422 
Muscle spasm 45 (41.7%) 59 (41.0%) 1.03 (0.62–1.71) 1 
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Variable 
Positive, N=108 
n (%) 
Negative, N=144 
n (%) 
Odds Ratio  
(95% CI*) 
P-value 
Hypersalivation 28 (25.9%) 38 (26.4%) 0.98 (0.55–1.72) 1 
Anxiety 33 (30.6%) 51 (35.4%) 0.80 (0.47–1.37) 0.50 
Hallucinations 26 (24.1%) 42 (19.2%) 0.77 (0.44–1.36) 0.39 
Autonomic 
instability 
29 (26.9%) 47 (32.6%) 0.76 (0.44–1.31) 0.34 
Agitation or 
combativeness 
55 (50.9%) 86 (59.7%) 0.70 (0.42–1.16) 0.20 
Nausea or vomiting 38 (35.2%) 66 (45.8%) 0.64 (0.38–1.07) 0.09 
Ataxia 20 (18.5%) 38 (26.4%) 0.63 (0.34–1.17) 0.17 
Anorexia 19 (17.6%) 37 (25.7%) 0.62 (0.33–1.15) 0.17 
Insomnia 11 (10.2%) 27 (18.8%) 0.49 (0.23–1.04) 0.08 
Confusion or 
delirium 
67 (62.0%) 123 (85.4%) 0.28 (0.15–0.51) <0.001† 
Seizures 27 (25.0%) 79 (54.9%) 0.27 (0.16–0.47) <0.001† 
Malaise or fatigue 39 (36.1%) 101 (70.1%) 0.24 (0.14–0.41) <0.001† 
Headache 29 (26.9%) 90 (62.5%) 0.22 (0.13–0.38) <0.001† 
* CI = Confidence interval, † Statistically significant 
Table 2. Signs and Symptoms Among Cases Testing Positive and Negative for Rabies 
3.6.2 Seasonality 
The onset of illness of rabies cases was more likely to occur during summer or fall months 
(May through October) when compared to non-rabies cases (OR 1.77; 95% CI 1.04–3.01). 
While no significant difference was observed between indigenous rabies cases and non-
rabies cases in the seasonal pattern of exposures to animals, the limited number of cases 
reporting a definite animal exposure was a limiting factor in this analysis. 
3.6.3 Signs and symptoms 
The presenting signs and symptoms of human rabies in the United States were often 
nonspecific such as fever, malaise, headache, weakness, fatigue, sore throat, and anorexia. 
The most commonly reported signs and symptoms reported among rabies cases during the 
course of illness were fever (83%), confusion or delirium (62%), agitation or combativeness 
(51%), paresthesia or localized pain (50%), and dysphagia (49%). In contrast, the most 
common signs and symptoms reported among non-rabies cases were confusion or delirium 
(85%), fever (78%), malaise or fatigue (70%), headache (63%), and agitation or combativeness 
(60%). When comparing these two groups, aerophobia, hydrophobia, and paresthesia or 
localized pain were more likely to be reported among rabies cases than non-rabies cases 
with an OR of 14.59, 7.50, and 5.86 respectively (P-values ≤ 0.001). Dysphagia and localized 
weakness were also more likely to occur among rabies cases with ORs of 2.73 and 2.26 (P-
values ≤ 0.004). Priapism or spontaneous ejaculation was reported more commonly among 
rabies cases (OR 2.73) but this finding did not reach statistical significance. Among non-
rabies cases, headache, malaise or fatigue, seizures, and confusion or delirium were more 
frequent than in rabies cases with ORs of 0.22–0.28 (P-values <0.001). Although not 
statistically significant, insomnia was also seen more often in non-rabies cases. Fever, muscle 
spasm, hypersalivation, anxiety, hallucinations, autonomic instability, agitation or 
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combativeness, nausea or vomiting, and ataxia all appeared to occur with equal likelihood 
in rabies and non-rabies cases. 
3.6.4 Laboratory values 
Laboratory values reported for the first collected samples of serum and CSF from rabies and 
non-rabies cases were compared. The serum white blood cells of rabies cases were elevated 
higher than non-rabies cases with mean values of 14.8 x 103 cells/µL (range 7.0–46.6 x 103 
cells/µL) and 12.1 x 103 cells/µL (range 2.9–29.4 x 103 cells/µL) for rabies and non-rabies 
cases respectively (P-value 0.009). Over 95% of both rabies and non-rabies cases reporting 
CSF values had an abnormal CSF white blood cell count, red blood cell count, protein, or 
glucose. The percentage of abnormal values for each of these tests was similar between 
rabies and non-rabies cases. The white blood cell count in CSF was elevated in both rabies 
cases and non-rabies cases with mean values of 61.3 cells/µL (range 0–1000 cells/µL) and 
89.0 cells/µL (range 0–980 cells/µL) respectively though this difference was not statistically 
significant (P-value 0.213). A lymphocytic predominance in CSF was seen in the majority of 
rabies cases. Rabies cases also demonstrated higher percentages of lymphocytes with a 
mean of 79% lymphocytes (range 31–100%) compared to a mean of 66% lymphocytes (range 
0–100%) in non-rabies cases (P-value 0.034). Segmented neutrophils in CSF were also found 
to be higher in rabies cases with a mean of 30% (range 1–99%) compared to a mean of 15% 
(range 0–97%) in non-rabies cases (P-value 0.013). Protein in CSF was elevated in both 
groups with mean values of 72.8 mg/dL (range 15.0–178.0 mg/dL) in rabies cases and 86.2 
mg/dL (range 4.0–1140.0) in non-rabies cases. This difference was not statistically significant 
(P-value 0.460). The mean value of glucose in CSF was elevated in rabies cases (85.8 mg/dL, 
range 24.0–211.0 mg/dL) while the mean of non-rabies cases was within the normal range 
(73.2 mg/dL, range 14.0–157.0 mg/dL) (P-value 0.004). No significant differences between 
rabies and non-rabies cases were found in CSF red blood cell counts, serum lymphocyte 
counts, serum segmented neutrophil counts, or serum glucose (P-values 0.193-0.781).  
3.7 Treatment 
Treatment of human rabies was successful in 4 cases. Of these, 2 had received rabies vaccine 
before the onset of illness. The first survivor (patient 18) became ill 2 days after completing a 
14-day course of duck embryo vaccine following a bat bite. The diagnosis of rabies was 
based on CSF RABV antibody detection and serum antibody titers most consistent with 
clinical infection in combination with compatible epidemiologic and clinical histories. This 
patient required intensive supportive care but recovered fully within 6 months after onset. 
The second survivor (patient 29) had onset of symptoms ~2 weeks after spraying 
suspensions of a modified live RABV strain while performing research as a laboratory 
technician. Diagnosis was confirmed by detection of CSF antibodies and rising RABV serum 
antibody titers. The patient had received pre-exposure prophylaxis with annual boosters 
and had demonstrated RABV antibodies in response to these vaccinations. It is 
hypothesized that the strain he was exposed to may have developed increased infectivity 
following passage through animal and cell culture systems (Gibbons, 2002). Following 
intensive medical care, the patient survived but was left with severe neurologic sequelae. 
The third survivor (patient 94) developed rabies after being bitten by a bat. RABV antibodies 
were found in both serum and CSF. She was treated with an experimental treatment 
protocol (later termed the Milwaukee Protocol) involving induction of coma and 
administration of antiviral agents and recovered with only minor residual deficits (Hu, 
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2007). The last survivor in this series (patient 103) showed clinical signs and symptoms of 
encephalitis 2 months after exposure to bats and RABV antibodies were detected in both 
serum and CSF prior to the administration of a single dose of rabies vaccine and rabies 
immune globulin. This patient made a full recovery without the need for intensive care. No 
RABV was identified from any of the surviving patients. 
Excluding the surviving cases, a total of 31 cases reported treatment after the onset of 
symptoms consisting of either administration of rabies immune globulin, immunization 
with rabies vaccine, induction of coma via the Milwaukee Protocol, or receipt of one or more 
antiviral medications including acyclovir, ganciclovir, amantadine, ribavirin, interferon, 
cytarabine, or adenine arabinoside. Thirteen patients were administered rabies immune 
globulin, 8 patients were immunized with rabies vaccine, 23 patients received antiviral 
therapy, and 5 patients underwent treatment with the Milwaukee Protocol during the 
course of illness. The median length of illness among all of those treated was longer when 
compared to those who did not receive any of the specified treatments (23.0 days vs. 13.0 
days, P-value 0.029 by Log-rank test). It may be that those who received treatment were also 
more likely to receive supportive care which has previously been seen to increase the length 
of illness (Anderson, 1984). When treatments were compared individually, the median 
length of illness was longer for patients receiving rabies vaccine (14.0 day versus 13.5 days), 
the Milwaukee Protocol (28.0 days versus 13.0 days), or antiviral therapy (17.0 day versus 
13.0 days) but shorter for patients receiving rabies immune globulin (13.0 days versus 14.0 
days). However, none of the differences for individual treatments reached statistical 
significance (P-value 0.198-0.537 by Log-rank test). Overall, the median length of illness was 
13.5 days (range 1–133 days).  
3.8 Postexposure prophylaxis of contacts of cases 
Data on administration of PEP was available in 71 cases (Table 1). A minimum of 3,359 
individuals received PEP due to contact with a human rabies patient with a median of 39 
individuals per case (range 1–180). The average number of individuals receiving PEP was 
greater in cases diagnosed postmortem compared to cases diagnosed antemortem (51 vs. 54) 
though this result was not statistically significant (P-value 0.453). The number of total risk 
assessments performed was reported for 22 cases. Typically 33% of individuals evaluated 
for RABV exposure received PEP per case (range 3–69%).  
3.9 Rabies virus diagnostic testing 
3.9.1 Antemortem test results 
Results of RABV laboratory diagnostic testing were collected and summarized for 62 
patients where specimens were collected prior to death (Table 3). When available, the 
number of days after illness onset the sample was collected (i.e. the sample collection date – 
illness onset date) is reported in parentheses following the test result. The cutaneous nerves 
of nuchal skin biopsies were tested for RABV antigen in 41 cases. A positive result was 
obtained in 24 cases (59%) with the first positive sample occurring a median of 7 days (range 
2-12 days) after illness onset. RABV was detected in corneal impressions in 9 of 19 cases 
(47%) with 3 (16%) reporting inconclusive results and 7 (37%) reporting negative results. 
RABV antigen was first detected in corneal impressions a median of 11 days (range 2-13 
days) after onset of rabies. Samples of brain were tested in 6 cases; 1 was inconclusive, 1 was 
negative, and 4 were first found positive a median of 12 days (range 7-21 days)  
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Table 3. Summary of Antemortem Diagnostic Test Results for 62 Patients with Human 
Rabies in the United States, 1960–2010 
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following onset of illness. Virus isolation from saliva was attempted in 23 cases and 
successful in 11 (48%) in samples collected a median of 8 days (range 3-13 days) after illness 
onset. RABV RNA was detected in 27 of 32 cases tested (84%) with the first positive results 
obtained from samples a median of 7 days (range 2-14 days) after the appearance of 
symptoms. Serum was tested for antibodies in 48 patients with no history of vaccination at 
the time of sample collection and was positive in 33 cases (69%). Antibodies in serum were 
first detected a median of 10.5 days (range 4-21 days) from the onset of illness in these 
unvaccinated patients. In contrast, antibodies in CSF were found in only 17 of 40 cases tested 
(43%) and first appeared a median of 14 days (range 5-28 days) following illness onset. 
3.9.2 Postmortem test results 
Confirmation of rabies through laboratory testing of postmortem samples was reported in 
81 cases. The confirmation came shortly after death in the majority of cases. However, in at 
least 14 cases rabies was not suspected prior to death and was diagnosed as part of a 
postmortem investigation. Notable among these cases were all of the cases involving 
transplantation of infected organs or tissue (patients 30-31 and 89-93), 2 cases (patient 71 and 
patient 72) initially evaluated for suspected Creutzfeldt-Jakob disease, 1 case (patient 76) 
referred for testing of an undiagnosed encephalitis to the California Encephalitis Project, 1 
case (patient 96) referred for testing to CDC’s Unexplained Deaths Project, and 1 case 
(patient 59) originally attributed to disseminated candidiasis and mucormycosis in a 
pregnant female. The delay in diagnosis for these cases ranged from 1 to 6 months after 
death. 
4. Conclusion 
Despite being indigenous in wildlife, human rabies was a rarely reported disease in the 
United States during 1960–2010. An average of 2 cases per year was recorded during this 
time period, a trend that remained largely stable throughout each decade. While this should 
be considered a great success of public health efforts towards prevention and control, the 
true incidence of human rabies is likely higher due to under recognition. The disease occurs 
so infrequently that most clinicians have little direct experience with rabies and therefore 
may not consider it in the differential diagnosis of patients presenting with encephalitis. The 
lack of a clear animal exposure preceding illness in increasing numbers of cases leaves 
clinicians without a significant clue that might prompt consideration of rabies. The myriad 
of other possible etiologies of encephalitis further compounds this problem. For these 
reasons, a clear diagnosis cannot be found in the majority of cases of encephalitis even when 
extensive testing to identify the cause of illness is employed (Glaser, 2003). In fact, between 
1979 and 1998 there was an average of over 1,000 deaths per year from encephalitis due to 
unknown cause reported in the United States (Khetsuriani, 2007). It is interesting to note 
that 1 of the 334 cases of encephalitis (0.3%) investigated by the California encephalitis 
project was diagnosed with rabies (Glaser, 2003). Rabies was not previously suspected in 
this patient and would almost certainly have remained unrecognized without the extensive 
testing performed as part of the study. Applying this rate of unrecognized rabies cases to the 
annual number of reported deaths due to encephalitis of unknown cause suggests there 
could be over 3 cases of human rabies that go unrecognized each year in the United States 
alone. This review provides a comprehensive summary of epidemiologic and clinical data of 
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all of the known cases within the last 5 decades which can be used as an aid in recognizing 
and identifying rabies among patients with encephalitis. 
The epidemiology of human rabies in the United States has undergone striking changes over 
the last century. Prior to the 1960s, the vast majority of human rabies cases in the United 
State were due to bites from an infected dog. Worldwide, dogs remain the primary source of 
human rabies (WHO, 2004; Knobel, 2005). However, a dramatic decline in human rabies 
cases in the United States occurred during the 1940s and 1950s as illustrated in Figure 2. This 
decrease in cases paralleled the improvement and application of new rabies vaccines for 
both humans and animals. Key to this approach was the targeting of domestic animals for 
vaccination to create a barrier of protection from RABV transmission to humans, a strategy 
that was ultimately successful in eliminating the canine RABV variant from the United 
States (Velasco-Villa, 2008). Throughout the 1940s and 1950s the number of human rabies 
cases attributed to domestic animals (primarily dogs) far exceeded those involving wildlife 
animals. However, a reversal in this relationship took place in the 1960s when the number of 
human rabies cases associated with wildlife surpassed those due to domestic animals, a 
trend that continues to this day. Currently the most frequently reported rabid animals in the 
United States are raccoons, bats, skunks, and foxes (Blanton, 2010). Clinicians should be 
aware that these species can therefore be considered high risk though must also be careful 
not to discount exposures to other known vector species.  
 
 
 
 
Fig. 2. Human Rabies Cases in the United States, 1946–2008 
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The increasing number of cases associated with bats illustrates the growing importance of 
this species in the epidemiology of rabies (Figure 2). The advancement and increased 
utilization of RABV variant typing methods has led to a greater understanding of rabies 
epidemiology, particularly with regards to the role of bats (Smith, 1992). Excluding cases 
acquired through transplantation of infected tissue, a total of 42 RABV variants associated 
with bats were identified in this series, yet 16 (38%) of these cases had no reported exposure 
history. Without the availability of antigenic and molecular typing, this epidemiologic link 
to bats likely would have remained unrecognized in these cases. Many times, possible 
contact between the patient and a bat was recalled only after a bat RABV variant had been 
identified. Excluding cases acquired through transplantation, a total of 41/46 (89%) 
indigenous cases have been associated with bats either through a reported bat exposure or 
identification of a bat variant. The most common species of bats associated with human 
cases through variant typing were the silver-haired bat and the tricolored bat (Lasionycteris 
noctivagans and Perimyotis subflavus). This is a somewhat curious finding considering that 
these species of insectivorous bats are considered to be solitary tree-dwelling bats and are 
infrequently submitted to public health laboratories for rabies diagnostic testing (Krebs, 
2000; Messenger, 2002; Blanton, 2010). However, there is some evidence suggesting that the 
RABV variants in these species have evolved genetic changes that may increase their 
infectivity (Morimoto, 1996; Dietzschold, 2000). Additional studies of bat RABV will 
undoubtedly improve understanding of the emergence, perpetuation, and epizootiology of 
this disease (Streicker, 2010). 
Classically, one expects human rabies cases to be preceded by an animal bite exposure. 
However, a definite history of a recent animal bite was reported in less than half of the 
cases in this series. The epidemiologic shift in the source of infection of human rabies in 
the United States provides one possible explanation for this observation. Bites from dogs 
or other carnivores are more likely to be recognized simply due to the size of the animal. 
A larger bite wound is also more likely to require medical treatment at which time 
consideration can be given to the need for rabies PEP. In contrast, North American bats 
are small and produce bite wounds that are superficial by comparison and less likely to 
require medical attention. With the advent of modern cell culture vaccines in 1980 and 
rabies immune globulin, no PEP failures have been reported in the United States. Unless 
the victim was previously aware of the risk of rabies from a bat bite, the opportunity for 
lifesaving PEP may be lost. A survey among cavers (spelunkers) in the United States 
found that 15% indicated a bat bite was not a risk for rabies, suggesting that a significant 
proportion of the public at large may also be unaware of the risk posed by bats (Gibbons, 
2002). Some bat bites go unnoticed entirely because bat teeth are small and sharp (Feder, 
1997). If the victim were engaged in an outdoor activity it is not hard to imagine a bat bite 
being confused for an insect bite or other minor trauma if the bat remained hidden in a 
tree or crevice (Gibbons, 2002). Furthermore, due to the extended incubation period a 
patient may not link the symptoms of the disease with an exposure that occurred months 
before the onset of illness. The median incubation in this series was nearly six weeks with 
evidence suggesting that long incubation periods on the order of years are possible 
(Smith, 1991). Thus, it is essential that the public be informed of the risk of rabies from all 
mammals and to remain vigilant for potential exposures, particularly when engaging in 
activities that put them at risk for contact with bats and other wildlife animals. Clinicians 
must also recognize that rabies should not be excluded from the differential diagnosis of a 
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patient with acute progressive encephalitis due to the absence of a recent animal exposure 
history. 
The initial signs and symptoms of human rabies are largely nonspecific and include fever, 
malaise, headache, nausea, and vomiting. Not surprisingly, almost half of the patients in this 
series were evaluated for their symptoms at least once prior to being admitted to the 
hospital without the diagnosis of rabies being considered. Thus, it may be very difficult to 
diagnose rabies during the prodromal phase in the absence of an animal exposure to alert 
one to the possibility. However, the progression of illness is rapid with most patients 
seeking medical care within one day of the appearance of symptoms and requiring 
hospitalization within 4 days of illness onset. Furthermore, most patients succumbed to their 
illness within 2 weeks of the onset of symptoms. These data suggest that rabies would be 
less likely in patients who do not require hospitalization within one week of developing 
symptoms or in hospitalized patients surviving longer than 2 weeks. Prioritization of testing 
for other etiologies over rabies would be prudent in these situations. However, several signs 
and symptoms were found to occur more frequently in patients with rabies when compared 
to patients with encephalopathy who tested negative for rabies. Aerophobia and 
hydrophobia were the most specific findings associated with rabies cases despite the fact 
that these symptoms were found in relatively few cases. Intubation and sedation have 
become common components of modern medical management of critically ill patients, a 
practice that may mask these symptoms unless specifically noted by patients early in their 
course. The neurologic findings of paresthesias or localized pain, dysphagia, and focal 
weakness were also positively linked to rabies cases. In contrast, headache, malaise or 
fatigue, seizures, and confusion or delirium were observed more frequently in non-rabies 
cases than in rabies cases.  
The clinical presentation of human rabies is often classified as either encephalitic (furious) or 
paralytic (dumb) rabies. The encephalitic form of the disease is characterized by overall 
hyperexcitability with episodes of confusion, agitation or aggressive behavior, and 
hallucinations. In the paralytic form, localized weakness and/or paralysis are the most 
prominent feature and are commonly accompanied by paresthesias, pruritis, or localized 
pain at the site of the bite and a normal mental status. The signs and symptoms associated 
with rabies cases in this series are those classically used to describe the paralytic rather than 
the encephalitic form. In general, 80% of human rabies patients are thought to manifest the 
encephalitic form while 20% have a paralytic form (Jackson, 2002)(Jackson, 2007). As such, 
clinicians may be more likely to submit cases for testing that resemble their preconceived 
notion of the more common furious form of human rabies and less likely to consider rabies 
with the more rare paralytic form. A connection between the paralytic form of rabies and 
transmission by vampire bats has been noted in several human rabies outbreaks (Nehaul, 
1955; Hurst, 1959; Hurst, 1959; Pawan, 1959; Verlinde, 1975; da Rosa, 2006). However, 
vampire bats do not cause exclusively paralytic disease as the encephalitic form has been 
described with a vampire bat human rabies outbreak in Peru (Lopez, 1992). Host factors 
most certainly play a role also as two individuals bitten by the same dog were seen to 
develop encephalitic rabies in one and paralytic rabies in the other (Hemachudha, 1988). 
Nevertheless, it is unclear whether the overall preponderance of cases linked to bats may 
have affected the clinical syndrome observed in this series. Regardless of the source of 
infection, clinicians should be aware that the clinical presentation of human rabies is a 
spectrum that can include features of either the encephalitic or paralytic forms. Positive 
indicators such as hydrophobia, aerophobia, paresthesias or localized pain, focal weakness, 
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and dysphagia in a patient with acute progressive encephalitis should alert the clinician to 
the possibility of rabies. 
The age and sex of a patient in addition to the month of illness onset may also provide clues 
to the diagnosis of rabies in patients with encephalitis. Globally, human rabies is most likely 
to be seen in children less than 15 years old (WHO, 2004). However, patients in this series 
were more likely to be older with a median age of 29 years. The disproportionate number of 
cases linked with bats and other wildlife species as opposed to dogs is likely responsible for 
this discrepancy. Children are more likely to unintentionally incite a dog attack through 
provoking behaviors and inexperience or because their size and movements may be similar 
to prey. With respect to wildlife, one might expect older age groups to be more likely to 
engage in outdoor activities or other behaviors that would put them at higher risk of 
exposure to bats and wildlife animals. Similarly, the predominance of males in this case 
series may also be due in part to males engaging in these activities more frequently than 
females. Limited data on the administration of PEP suggests that males may have higher 
rates of PEP (Helmick, 1983) though this trend was not confirmed in other studies of state 
level data (Blanton, 2005; O'Bell, 2006). Furthermore, males may be less likely to seek PEP 
after an exposure occurs. In support of this claim is evidence suggesting that the perception 
and awareness of health-related risks may be lower in males compared to females (Naslund, 
1997; Gustafson, 1998). The observation that most cases occurred during fall months 
corresponds well with the observation that most contact with wildlife, particularly bats, 
occurs during the late summer months (Messenger, 2002). Assuming an incubation period 
of 1-3 months, exposures occurring during summer would then be expected to become ill 
during the fall. This pattern was particularly significant when analyzing cases associated 
with bats. Most bat exposures occurred during the early fall months and is consistent with 
previous research demonstrating that the incidence of rabies-infected bats peaks in August 
(Constantine, 1979; Pape, 1999). Furthermore, the illness onset month in cases associated 
with bats was most common during the late fall months. Both exposures and onset of illness 
were more likely to occur in fall months in cases associated with bats compared with those 
not associated with bats. Based on these findings, a typical human rabies case in the United 
States would be a young adult male presenting with signs and symptoms of encephalitis in 
the fall. 
When human rabies is suspected it is important to initiate diagnostic testing as early as 
possible. Current guidelines for antemortem testing of human patients recommend the 
collection of samples of skin, serum, saliva, and CSF. In this series, the earliest positive 
results were found with detection of viral RNA in saliva and viral antigen in skin after a 
median of 7 days following onset of illness. The earliest diagnosis occurred in patient 98 
with both saliva and skin collected 2 days after illness onset reported positive by PCR and 
DFA respectively on the sixth day of illness. Virus isolation from saliva was also fairly rapid 
with positive results obtained as early as 3 days after illness onset (median 8 days). The 
development of a humoral immune response lags behind the secretion of virus in saliva and 
antibodies were detected in serum and CSF a median of 10 and 14 days respectively 
following the appearance of symptoms. The earliest detection of rabies specific antibodies 
after illness onset was 4 days in serum and 5 days in CSF. With respect to sensitivity, 
identification of viral RNA in saliva was the most sensitive testing modality with 84% of 
rabies cases tested giving positive results. Detection of antibodies in serum and viral 
antigens in brain and cutaneous nerves were also relatively sensitive with positive results in 
69%, 67%, and 59% of cases tested respectively. Though isolation of RABV from saliva was 
 Non-Flavivirus Encephalitis 
 
268 
successful in fewer than half of cases, the utility of virus isolates for variant typing, 
comparative analyses, investigations of pathogenesis, and other studies is invaluable. 
Similarly, while antibodies in CSF were found relatively infrequently, their detection is 
significant as this finding alone is considered diagnostic for rabies regardless of history of 
rabies vaccination (Moore, 2010). Examination of corneal impressions was positive in only 
47% of cases tested and is no longer routinely used for antemortem diagnostic testing given 
the risk of damage to the eyes when performed by inexperienced practitioners and the 
relatively poor sensitivity. While the sensitivity of viral antigen detection in antemortem 
brain samples is high, routine testing of these samples is not recommended due to the 
invasiveness of the collection procedure. The best approach for maximizing the sensitivity 
and accuracy of antemortem diagnostic rabies testing is through submission of skin, saliva, 
serum, and CSF for evaluation with multiple modalities including detection of viral antigen, 
viral nucleic acid, and rabies specific antibodies, especially because some test results become 
available in less than 24 hours.  
The diagnosis of human rabies can be essential in preventing further cases. Identifying 
human cases allows for a public health response to investigate the source of infection and 
provide risk assessments of contacts with potential exposures. If a suspected animal source 
infestation is discovered, these animals can be removed to avert any further exposures and 
tested to confirm whether additional animals are rabid. Any individuals with contact with 
potentially rabid animals can then be assessed for exposures and given PEP when indicated. 
Public education can also be targeted to increase awareness of the risk of rabies transmission 
from reservoir species and the importance of seeking medical attention promptly if an 
exposure does occur. Contacts of rabies patients should also be identified and evaluated for 
exposures. Although human-to-human transmission of rabies has only been well 
documented in cases of organ or tissue transplantation, transmission following exposure to 
human saliva or nervous tissue remains a theoretical possibility (Helmick, 1987). Rare 
anecdotal reports of direct human to human transmission of rabies through bites, kissing, 
lactation, intercourse, transplacental transmission, and delivery of healthcare have been 
reported though possible animal exposures were difficult to exclude and none of these cases 
were laboratory confirmed (Helmick, 1987; Gibbons, 2002). Healthcare providers can be 
reassured by the fact that no case of rabies has ever been confirmed in a caregiver of any of 
the estimated 55,000 cases occurring each year. Moreover, early recognition and contact 
isolation of suspected cases are effective means of limiting exposures in healthcare settings 
(Helmick, 1987). Given these facts, the median of 39 individuals receiving PEP per case 
found in this series may seem excessive. Though the higher rate of PEP of contacts among 
cases diagnosed postmortem compared to antemortem was not statistically significant, it is 
still likely that early diagnosis of human rabies will lead to fewer exposures and decrease 
unnecessary PEP. Lastly, identification of human rabies can avoid transmitting the virus 
through organ and tissue transplantation. Even if the diagnosis is made after transplantation 
has already taken place, removal of the transplanted tissue and administration of PEP has 
been successful in preventing infection in two recipients of corneas from an infected donor 
(Vetter, 2011).  
The early diagnosis of rabies also provides the best opportunity for experimental therapy of 
victims. The 4 survivors reported in this series demonstrate that survival is rare but does 
occur. In addition, patient 95 was the first report of a patient recovering from rabies without 
receiving any vaccination against rabies through the use of the Milwaukee Protocol. Two 
subsequent survivors attributed to the application of this protocol have been reported 
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among 24 attempts to give an estimated 9% survival by intention-to-treat analysis 
(Willoughby, 2009). As knowledge is gained from both treatment failures and successes, 
further refinement of this approach may increase the rate of success. The recovery of patient 
104 without application of the Milwaukee Protocol or even need for intensive care is the 
only well documented case of a presumed human abortive rabies infection. This case hints 
at the possibility that there may be a much larger spectrum of disease in rabies cases that has 
not been previously appreciated. It may be only recently recognized due to improved 
laboratory diagnostic techniques, greater availability of laboratory testing, or increased 
awareness of the possibility of rabies after several high profile cases in the United States 
including the survival of patient 95 and the cases transmitted through transplantation 
(patients 90-93). The association of both of these survivors with exposures to bats has also 
led to the hypothesis that canine RABV variants may be more virulent than bat variants 
(Lafon, 2005). However, one case of documented human rabies of canine origin in 
Equatorial Guinea purportedly survived infection with application of the Milwaukee 
Protocol, but later succumbed (Rubin, 2009). The patient’s death on hospital day 22 was 
thought to be due to complications of malnutrition. Irrespective of the source of infection, 
the limited success of treatment attempts emphasizes the importance of prevention. Current 
treatment protocols require considerable expense and advanced medical facilities making 
practical application unrealistic in many countries. In contrast, rabies prevention strategies 
implementing safe, efficacious, and affordable human and animal vaccines have proven to 
be highly effective, particularly in combination with community outreach and education 
programs (Rupprecht, 2008; Cleaveland, 2010). 
The results of this study are subject to several limitations. Given the relative rarity of human 
rabies in the United States despite the abundance of the disease in nature, this case series 
represents a relatively small sample size and several cases had only limited data available. 
In addition, all of the data from cases were collected retrospectively and are therefore 
subject to recall bias. Histories of potential animal exposures may be particularly sensitive to 
poor memory given the lengthy incubation period seen with rabies; this may be exacerbated 
in cases where rabies was not initially considered or the diagnosis was delayed. In all cases 
there is a short window of opportunity to communicate directly with patients due to the 
rapid progression of disease and nearly universal fatal outcome. In the confirmed rabies 
cases additional clinical and laboratory data were gained through public health 
investigations. In contrast, data from non-rabies cases relied primarily on patient 
information forms completed at the time of submission for diagnostic testing. As such, those 
data represent only a snapshot of the clinical picture making comparisons of temporal 
patterns in rabies and non-rabies cases unfeasible. Moreover, no follow-up of clinical 
outcomes (i.e. survival or death) was available for non-rabies cases. Though statistically 
significant results were obtained, it is possible that other significant findings may have been 
missed due to the small sample size. 
This review complements previous reports of smaller series of human rabies cases in the 
United States (Held, 1967; Anderson, 1984; Noah, 1998; CDC, 2006). Significant changes in 
the epidemiology of rabies include the increasing role of bats in human rabies and the 
concomitant rise in cases with no clear history of animal exposure. These findings 
underscore the need to increase public awareness of the risk of rabies from wildlife, 
particularly bats, and the importance of prompt medical evaluation if contact with such 
animals occurs. Advances in the treatment of human rabies have led to the first reported 
cases of recovery without immunization with rabies vaccine. These survivors raise hope 
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for continued advancements in the efforts to develop a treatment for rabies. Identification 
of the first presumptive abortive human rabies case suggests an expanded view of the 
continuum of disease caused by lyssaviruses is necessary. Our knowledge of human 
rabies will continue to grow as more cases are identified. As such, increasing the 
recognition and diagnosis of human rabies will not only enhance our understanding of 
the disease but ultimately will save human lives as well. Early diagnosis allows the 
institution of proper biosafety and isolation precautions of rabies patients as well as the 
initiation of public health action to identify potential exposures to evaluate their need for 
PEP. Insights gained from human rabies may also prove to be applicable to other 
zoonoses. As one of the earliest known zoonotic diseases, rabies can be used as a 
prototype in investigating the interplay between animals and their impact on human 
health. This relationship is becoming increasingly important as the majority of emerging 
infectious diseases are now recognized to be zoonotic in nature. Lyssavirus infections and 
human rabies due to bats should be considered emerging infectious threats themselves. 
Research into bats and human disease is particularly relevant given the identification of 
bats as the reservoir of numerous other human pathogens including Ebola virus, Marburg 
virus, nipah virus, hendra virus, and SARS-like coronaviruses among others (Calisher, 
2006). Clearly, the health of humans, animals, and the environment are interconnected 
and lessons learned from rabies are extremely valuable in relation to this concept of “One 
Health.”   
5. Acknowledgements  
The authors thank all of the clinicians and public health professionals who provided 
clinical, epidemiologic, and laboratory data on these cases. The authors also recognize the 
contributions of Jesse Blanton, Lizette Durand, Richard Franka, Felix Jackson, Ivan 
Kuzmin, Lillian Orciari, Dustyn Palmer, Sergio Recuenco, Andres Velasco-Villa, and Pam 
Yager. 
6. References 
Anderson, L. J., K. G. Nicholson, et al. (1984). "Human rabies in the United States, 1960 
to 1979: epidemiology, diagnosis, and prevention." Ann Intern Med 100(5): 728-
735. 
Blanton, J. D., N. Y. Bowden, et al. (2005). "Rabies postexposure prophylaxis, New York, 
1995-2000." Emerg Infect Dis 11(12): 1921-1927. 
Blanton, J. D., D. Palmer, et al. (2010). "Rabies surveillance in the United States during 2009." 
J Am Vet Med Assoc 237(6): 646-657. 
Calisher, C. H., J. E. Childs, et al. (2006). "Bats: important reservoir hosts of emerging 
viruses." Clin Microbiol Rev 19(3): 531-545. 
CDC (2006). 
CDC (2006). Protocol for Postmortem Diagnosis of Rabies in Animals by Direct Fluorescent 
Antibody Testing. 
Christian, K. A., J. D. Blanton, et al. (2009). "Epidemiology of rabies post-exposure 
prophylaxis--United States of America, 2006-2008." Vaccine 27(51): 7156-7161. 
 Human Rabies Epidemiology and Diagnosis 
 
271 
Cleaveland, S., P. Costa, et al. (2010). "Catalysing action against rabies." Vet Rec 167(11): 422-
423. 
Constantine, D. G. (1979). "An updated list of rabies-infected bats in North America." J Wildl 
Dis 15(2): 347-349. 
da Rosa, E. S., I. Kotait, et al. (2006). "Bat-transmitted human rabies outbreaks, Brazilian 
Amazon." Emerg Infect Dis 12(8): 1197-1202. 
Dietzschold, B., K. Morimoto, et al. (2000). "Genotypic and phenotypic diversity of rabies 
virus variants involved in human rabies: implications for postexposure 
prophylaxis." J Hum Virol 3(1): 50-57. 
Feder, H. M., Jr., R. Nelson, et al. (1997). "Bat bite?" Lancet 350(9087): 1300. 
Gibbons, R. V. (2002). "Cryptogenic rabies, bats, and the question of aerosol transmission." 
Ann Emerg Med 39(5): 528-536. 
Gibbons, R. V., R. C. Holman, et al. (2002). "Knowledge of bat rabies and human exposure 
among United States cavers." Emerg Infect Dis 8(5): 532-534. 
Glaser, C. A., S. Gilliam, et al. (2003). "In search of encephalitis etiologies: diagnostic 
challenges in the California Encephalitis Project, 1998-2000." Clin Infect Dis 36(6): 
731-742. 
Gustafson, P. E. (1998). "Gender differences in risk perception: theoretical and 
methodological perspectives." Risk Anal 18(6): 805-811. 
Held, J. R., E. S. Tierkel, et al. (1967). "Rabies in man and animals in the United States, 1946-
65." Public Health Rep 82(11): 1009-1018. 
Hellenbrand, W., C. Meyer, et al. (2005). "Cases of rabies in Germany following organ 
transplantation." Euro Surveill 10(2): E050224 050226. 
Helmick, C. G. (1983). "The epidemiology of human rabies postexposure prophylaxis, 1980-
1981." Jama 250(15): 1990-1996. 
Helmick, C. G., R. V. Tauxe, et al. (1987). "Is there a risk to contacts of patients with rabies?" 
Rev Infect Dis 9(3): 511-518. 
Hemachudha, T., P. Phanuphak, et al. (1988). "Immunologic study of human encephalitic 
and paralytic rabies. Preliminary report of 16 patients." Am J Med 84(4): 673-677. 
Houff, S. A., R. C. Burton, et al. (1979). "Human-to-human transmission of rabies virus by 
corneal transplant." N Engl J Med 300(11): 603-604. 
Hu, W. T., R. E. Willoughby, Jr., et al. (2007). "Long-term follow-up after treatment of rabies 
by induction of coma." N Engl J Med 357(9): 945-946. 
Hurst, E. W. and J. L. Pawan (1959). "A further account of the Trinidad outbreak of acute 
rabic myelitis: histology of the experimental disease." Caribb Med J 21: 25-45. 
Hurst, E. W. and J. L. Pawan (1959). "An outbreak of rabies in Trinidad without history of 
bites, and with the symptoms of acute ascending myelitis." Caribb Med J 21: 11-24. 
Jackson, A. C., M. J. Warrell, et al. (2003). "Management of rabies in humans." Clin Infect Dis 
36(1): 60-63. 
Jackson, A. C. and W. H. Wunner (2002). Rabies. Amsterdam ; Boston, Academic Press. 
Javadi, M. A., A. Fayaz, et al. (1996). "Transmission of rabies by corneal graft." Cornea 15(4): 
431-433. 
Khetsuriani, N., R. C. Holman, et al. (2007). "Trends in encephalitis-associated deaths in the 
United States." Epidemiol Infect 135(4): 583-591. 
 Non-Flavivirus Encephalitis 
 
272 
Knobel, D. L., S. Cleaveland, et al. (2005). "Re-evaluating the burden of rabies in Africa and 
Asia." Bull World Health Organ 83(5): 360-368. 
Krebs, J. W., J. S. Smith, et al. (2000). "Mammalian reservoirs and epidemiology of rabies 
diagnosed in human beings in the United States, 1981-1998." Ann N Y Acad Sci 916: 
345-353. 
Kusne, S. and J. Smilack (2005). "Transmission of rabies virus from an organ donor to four 
transplant recipients." Liver Transpl 11(10): 1295-1297. 
Kuzmin, I. V., I. S. Novella, et al. (2009). "The rhabdoviruses: biodiversity, phylogenetics, 
and evolution." Infect Genet Evol 9(4): 541-553. 
Lafon, M. (2005). "Bat rabies--the Achilles heel of a viral killer?" Lancet 366(9489): 876-877. 
Lopez, A., P. Miranda, et al. (1992). "Outbreak of human rabies in the Peruvian jungle." 
Lancet 339(8790): 408-411. 
Messenger, S. L., J. S. Smith, et al. (2002). "Emerging epidemiology of bat-associated cryptic 
cases of rabies in humans in the United States." Clin Infect Dis 35(6): 738-747. 
Moore, S. M. and C. A. Hanlon (2010). "Rabies-specific antibodies: measuring surrogates of 
protection against a fatal disease." PLoS Negl Trop Dis 4(3): e595. 
Morimoto, K., M. Patel, et al. (1996). "Characterization of a unique variant of bat rabies virus 
responsible for newly emerging human cases in North America." Proc Natl Acad 
Sci U S A 93(11): 5653-5658. 
Naslund, G. K. (1997). "Relationships between health behavior, knowledge, and beliefs 
among Swedish blue-collar workers." Scand J Soc Med 25(2): 100-110. 
Nehaul, B. B. (1955). "Rabies transmitted by bats in British Guiana." Am J Trop Med Hyg 
4(3): 550-553. 
Noah, D. L., C. L. Drenzek, et al. (1998). "Epidemiology of human rabies in the United States, 
1980 to 1996." Ann Intern Med 128(11): 922-930. 
O'Bell, S. A., J. McQuiston, et al. (2006). "Human rabies exposures and postexposure 
prophylaxis in South Carolina, 1993-2002." Public Health Rep 121(2): 197-202. 
Pape, W. J., T. D. Fitzsimmons, et al. (1999). "Risk for rabies transmission from encounters 
with bats, Colorado, 1977-1996." Emerg Infect Dis 5(3): 433-437. 
Pawan, J. L. (1959). "Rabies in the vampire bat of Trinidad, with special reference to the 
clinical course and the latency of infection." Caribb Med J 21: 137-156. 
Rubin, J., D. David, et al. (2009). "Applying the Milwaukee protocol to treat canine rabies in 
Equatorial Guinea." Scand J Infect Dis 41(5): 372-375. 
Rupprecht, C. E., J. Barrett, et al. (2008). "Can rabies be eradicated?" Dev Biol (Basel) 131: 95-
121. 
Smith, J. S., D. B. Fishbein, et al. (1991). "Unexplained rabies in three immigrants in the 
United States. A virologic investigation." N Engl J Med 324(4): 205-211. 
Smith, J. S., L. A. Orciari, et al. (1992). "Epidemiologic and historical relationships among 87 
rabies virus isolates as determined by limited sequence analysis." J Infect Dis 166(2): 
296-307. 
Srinivasan, A., E. C. Burton, et al. (2005). "Transmission of rabies virus from an organ donor 
to four transplant recipients." N Engl J Med 352(11): 1103-1111. 
Streicker, D. G., A. S. Turmelle, et al. (2010). "Host phylogeny constrains cross-species 
emergence and establishment of rabies virus in bats." Science 329(5992): 676-679. 
 Human Rabies Epidemiology and Diagnosis 
 
273 
Velasco-Villa, A., S. A. Reeder, et al. (2008). "Enzootic rabies elimination from dogs and 
reemergence in wild terrestrial carnivores, United States." Emerg Infect Dis 14(12): 
1849-1854. 
Verlinde, J. D., E. Li-Fo-Sjoe, et al. (1975). "A local outbreak of paralytic rabies in Surinam 
children." Trop Geogr Med 27(2): 137-142. 
Vetter, J. M., L. Frisch, et al. (2011). "Survival after transplantation of corneas from a rabies-
infected donor." Cornea 30(2): 241-244. 
WHO (2004). WHO Expert Consultation on Rabies. First Report. WHO technical report 
series No 931. Geneva, WHO. 2005: 121. 
Willoughby, R. E., Jr. (2009). ""Early death" and the contraindication of vaccine during 
treatment of rabies." Vaccine 27(51): 7173-7177. 
7. Case references 
[1] CDC (1960). Human rabies. Morbidity and Mortality Weekly Report, Vol.9, No.31, p.2 
[2] Ross, E.; Armentrout, S. (1962). Myocarditis Associated with Rabies: Report of a Case. 
New England Journal of Medicine, Vol.266, No.21, pp.1087-1089 
[3] CDC (1961). Human Rabies — Kentucky. Morbidity and Mortality Weekly Report, 
Vol.10, No.2, p.2 
[4] CDC (1961). Human Rabies — California. Morbidity and Mortality Weekly Report, 
Vol.10, No.3, p.2 
[5] CDC (1961). Human Rabies — Kentucky. Morbidity and Mortality Weekly Report, 
Vol.10, No.26, p.8 
[6] CDC (1962). Rabies in Man — Texas. Morbidity and Mortality Weekly Report, Vol.11, 
p.258 
[7] CDC (1962). Human Rabies — Idaho. Morbidity and Mortality Weekly Report, Vol.11, 
pp.395,400 
[8] CDC (1963). Human Rabies Death — Alabama. Morbidity and Mortality Weekly Report, 
Vol.12, p.300 
[9] Gomez M.; Siekert R. & Hermann E. (1965). A Human Case of Skunk Rabies. Journal of 
the America Medical Association, Vol.194, , pp.333-335 
[10] CDC (1965). Human Rabies Death — West Virginia. Morbidity and Mortality Weekly 
Report, Vol.14, p.195 
[11] Bell, G. (1967). Death from Rabies in a Ten-Year-Old Boy (One of Two Cases in United 
States in 1966). South Dakota Journal of Medicine, Vol.20, pp.28-30 
[12] CDC (1967). Case of Imported Rabies — New York. Morbidity and Mortality Weekly 
Report, Vol.16, p.258 
[13] Cereghino, J.; Mason, L. & Sheehan, T. (1968). A Case of Rabies Encephalitis. Northwest 
Medcine, Vol.67, pp.857-860 
[14] Rubin, R.; Sullivan, L.; Summers, R.; Gregg, M. & Sikes, K. (1970). A Case of Human 
Rabies in Kansas: Epidemiologic, Clinical, and Laboratory Considerations. Journal 
of Infectious Diseases, Vol.122, pp.318-322 
[15] Emmons, R.; Leonard, L.; Degenaro, F.; Protas, E.; Bazeley, P.; Giamonna, S. & 
Sturckow, K. (1973). A Case of Human Rabies with Prolonged Survival. 
Intervirology, Vol.1, pp.60-72 
 Non-Flavivirus Encephalitis 
 
274 
[16] Hattwick, M.; Hochberg, F.; Landrigan, P. & Gregg, M. (1972). Skunk-Associated 
Human Rabies. Journal of the American Medical Association, Vol.122, No.1, pp.44-
47 
[17] Hattwick, M.; Weis, T.; Stechschulte, C.; Baer, G. & Gregg, M. (1972). Recovery from 
Rabies: A Case Reprt. Annals of Internal Medicine, Vol.76, pp.931-942 
[18] Bhatt, D.; Hattwick, M.; Gerdsen, R.; Emmons, R. & Johnson, H. (1977). Human Rabies: 
Diagnosis, Complications, and Management. American Journal of Diseases of 
Children, Vol.127, pp.862-869 
[19] CDC (1971). Human Rabies — New Jersey. Morbidity and Mortality Weekly Report, 
Vol.20, No.51, pp.459-460 
[20] CDC (1972). Human Rabies — California. Morbidity and Mortality Weekly Report, 
Vol.21, No.9, pp.73-74 
[21] Winkler, H.; Fashinell, T.; Leffingwell, L.; Howard, P. & Conomy, J. (1973). Airborne 
Rabies Transmission in a Laboratory Worker. Journal of the American Medical 
Association, Vol.126, No.10, pp.1219-1221 
[22] CDC (1973). Human Rabies — Kentucky. Morbidity and Mortality Weekly Report, 
Vol.22, No.39, pp.325-326 
[23] Sung, J.; Hayano, M.; Mastri, A. & Okagaki, T. (1976). A Case of Human Rabies and 
Ultrastructure of the Negri Body. Journal of Neuropathology and Experimental 
Neurology, Vol.35, pp.541-559 
[24] CDC (1976). Human Rabies — Puerto Rico. Morbidity and Mortality Weekly Report, 
Vol.24, pp.94,99 
[25] Baraff, L.; Hafkin, B.; Wehrle, P.; Emmons, R.;Gunn, R.; Overturf, G. & Steinberg, E. 
(1978). Human Rabies. The Western Journal of Medicine, Vol.128, pp.159-164 
[26] CDC (1976). Human Rabies — Maryland. Morbidity and Mortality Weekly Report, 
Vol.25, pp.235-236 
[27] CDC (1977). Human Rabies — Texas. Morbidity and Mortality Weekly Report, Vol.26, 
pp.31-32 
[28] CDC (1977). Rabies in a Laboratory Worker — New York. Morbidity and Mortality 
Weekly Report, Vol.26, pp.183-184 
[29] Houff, S.; Burton, R.; Wilson, R.; Henson, T.;London, W.; Baer, G.;Anderson, L.; 
Winkler, W.; Madden, D. & Sever, J. (1979). Human-To-Human Transmission of 
RABV by Corneal Transplant. The New England Journal of Medicine, Vol.300, 
No.11, pp.603-604 
[30] CDC (1978). Human Rabies — Texas. Morbidity and Mortality Weekly Report, Vol.27, 
p.267 
[31] CDC (1979). Human Rabies — Pennsylvania. Morbidity and Mortality Weekly Report, 
Vol.28, pp.75-76,81 
[32] CDC (1979). Two Suspected Cases of Human Rabies — Texas, Washington. Morbidity 
and Mortality Weekly Report, Vol.28, p.292,297-298 
[33] CDC (1979). Human Rabies — United States. Morbidity and Mortality Weekly Report, 
Vol.28, pp.315-316,321 
[34] CDC (1979). Human Rabies — California. Morbidity and Mortality Weekly Report, 
Vol.28, pp.435-436 
 Human Rabies Epidemiology and Diagnosis 
 
275 
[35] CDC (1979). Human Rabies — Oklahoma. Morbidity and Mortality Weekly Report, 
Vol.28, pp.476-481 
[36] CDC (1979). Human Rabies — Kentucky. Morbidity and Mortality Weekly Report, 
Vol.28, pp.590-591 
[37] CDC (1981). Human Rabies — Oklahoma. Morbidity and Mortality Weekly Report, 
Vol.30, pp.343-344,349 
[38] CDC (1981). Human Rabies Acquired Oustide the United States from a Dog Bite. 
Morbidity and Mortality Weekly Report, Vol.30, No.43, pp.537-540 
[39] CDC (1983). Imported Human Rabies. Morbidity and Mortality Weekly Report, Vol.32, 
No.6, pp.78-80,85-86 
[40] CDC (1983). Human Rabies — Michigan. Morbidity and Mortality Weekly Report, 
Vol.32, No.12, pp.159-160 
[41] CDC (1984). Human Rabies — Texas. Morbidity and Mortality Weekly Report, Vol.33, 
No.33, pp.469-470 
[42] Smith, J.; Fishbein, D.; Rupprecht, C. & Clark, K. (1991). Unexplained Rabies in Three 
Immigrants in the United States. The New England Journal of Medicine, Vol.324, 
pp.205-211 
[43] CDC (1984). Human Rabies — Pennsylvania. Morbidity and Mortality Weekly Report, 
Vol.33, No.45, pp.633-635 
[44] CDC (1985). Human Rabies Acquired Outside the United States. Morbidity and 
Mortality Weekly Report, Vol.34, No.17, pp.235-236 
[45] CDC (1985). Human Rabies Diagnosed 2 Months Postmortem — Texas. Morbidity and 
Mortality Weekly Report, Vol.34, No.46, pp.700,705-707 
[46] CDC (1988). Human Rabies — California, 1987. Morbidity and Mortality Weekly 
Report, Vol.37, No.19, pp.305-308 
[47] Dempsey, D. (1990). The Case of the Missing Animal. The Pediatric Infectious Diseases 
Journal. Vol.9, No.1, pp.49-50 
[48] CDC (1989). Human Rabies — Oregon, 1989. Morbidity and Mortality Weekly Report, 
Vol.38, No.19, pp.335-337 
[49] CDC (1991). Human Rabies — Texas, 1990. Morbidity and Mortality Weekly Report, 
Vol.40, No.8, pp.132-133 
[50] CDC (1991). Human Rabies — Texas, Arkansas, and Georgia, 1991. Morbidity and 
Mortality Weekly Report, Vol.40, No.44, pp.765-769 
[51] CDC (1992). Human Rabies — California, 1992. Morbidity and Mortality Weekly 
Report, Vol.41, No.26, pp.461-463 
[52] CDC (1993). Human Rabies — New York, 1993. Morbidity and Mortality Weekly 
Report, Vol.42, No.41, pp.799,805-806 
[53] CDC (1994). Human Rabies — Texas and California, 1993. Morbidity and Mortality 
Weekly Report, Vol.43, No.6, pp.93-96 
[54] CDC (1994). Human Rabies — California, 1994. Morbidity and Mortality Weekly 
Report, Vol.43, No.25, pp.455-457 
[55] CDC (1994). Human Rabies — Miami, 1994. Morbidity and Mortality Weekly Report, 
Vol.43, No.42, pp.773-775 
 Non-Flavivirus Encephalitis 
 
276 
[56] CDC (1995). Human Rabies — Alabama, Tennessee, and Texas, 1994. Morbidity and 
Mortality Weekly Report, Vol.44, No.14, pp.269-272 
[57] CDC (1995). Human Rabies — West Virginia, 1994. Morbidity and Mortality Weekly 
Report, Vol.44, No.5, pp.86-87,93 
[58] CDC (1995). Human Rabies — Washington, 1995. Morbidity and Mortality Weekly 
Report, Vol.44, No.34, pp.625-627 
[59] CDC (1996). Human Rabies — California, 1995. Morbidity and Mortality Weekly 
Report, Vol.45, No.17, pp.353-356 
[60] CDC (1996). Human Rabies — Connecticut, 1995. Morbidity and Mortality Weekly 
Report, Vol.45, No.10, pp.207-209 
[61] CDC (1996). Human Rabies — Florida, 1996. Morbidity and Mortality Weekly Report, 
Vol.45, No.33, pp.719-720,727 
[62] CDC (1997). Human Rabies — New Hampshire, 1996. Morbidity and Mortality Weekly 
Report, Vol.46, No.12, pp.267-270 
[63] Scully, R.; Mark, E.; Mcneely, W.; Ebeling, S. & Phillips, L. (1998). Case 21-1998 — A 32-
Year-Old Woman with Pharyngeal Spasms and Paresthesias after a Dog Bite. The 
New England Journal of Medicine, Vol.339, No.2, pp.105-112 
[64] CDC (1997). Human Rabies — Kentucky and Montana, 1996. Morbidity and Mortality 
Weekly Report, Vol.46, No.18, pp.397-400 
[65] CDC (1997). Human Rabies — Montana and Washington, 1997. Morbidity and 
Mortality Weekly Report, Vol.46, No.33, pp.770-774 
[66] CDC (1998). Human Rabies — Texas and New Jersey, 1997. Morbidity and Mortality 
Weekly Report, Vol.47, No.1, pp.1-5 
[67] CDC (1999). Human Rabies — Virginia, 1998. Morbidity and Mortality Weekly Report, 
Vol.48, No.5, pp.95-97 
[68] CDC (2000). Human Rabies — California, Georgia, Minnesota, New York, and 
Wisconsin, 2000. Morbidity and Mortality Weekly Report, Vol.49, No.49, pp.1111-
1115 
[69] Soun, V.; Eidson, M.; Trimarchi, C.; Drabkin, P; Leach, R.; Wallace, B.; Jones, G.; 
Cantiello, K.; Qian, J. (2006). Antemortem Diagnosis of New York Human Rabies 
Case and Review of U.S. Cases. International Journal of Biomedical Science. Vol. 2, No. 
4, (December 2006), pp.433-444 
[70] Krebs, J.; Noll, H.; Rupprecht, C.; Childs, J. (2002). Rabies surveillance in the United 
States during 2001. Journal of the American Veterinary Medical Association. Vol. 221, 
No. 12, (December 2002), pp.1690-1701 
[71] CDC (2002). Human Rabies — California, 2002. Morbidity and Mortality Weekly 
Report, Vol.51, No.31, pp.686-688 
[72] CDC (2002). Human Rabies — Tenessee, 2002. Morbidity and Mortality Weekly Report, 
Vol.51, No.37, pp.828-829 
[73] CDC (2003). Human Rabies — Iowa, 2002. Morbidity and Mortality Weekly Report, 
Vol.52, No.3, pp.47-48 
[74] CDC (2003). First Human Death Associated with Raccoon Rabies — Virginia, 2003. 
Morbidity and Mortality Weekly Report, Vol.52, No.45, pp.1102-1103 
 Human Rabies Epidemiology and Diagnosis 
 
277 
[75] Krebs, J.; Mandel, E.; Swerdlow, D.; Rupprecht, C. (2004). Rabies surveillance in the 
United States during 2003. Journal of the American Veterinary Medical Association. Vol. 
225, No. 12, (December 2004), pp.1837-1849 
[76] CDC (2004). Human Rabies Death Associated with Bat Rabies — California, 2003. 
Morbidity and Mortality Weekly Report, Vol.53, No.2, pp.33-35 
[77] CDC (2005). Human Rabies — Florida, 2004. Morbidity and Mortality Weekly Report, 
Vol.54, No.31, pp.767-769 
[78] CDC (2004). Investigations of Rabies Infections in Organ Donor and Transplant 
Recipients — Alabama, Arkansas, Oklahoma, and Texas, 2004. Morbidity and 
Mortality Weekly Report, Vol.53, pp.1-3 
[79] Srinivasan, A.; Burton, E.; Kuehnert, M.; et al (2005). Transmission of RABV from an 
organ donor to four transplant recipients. The New England Journal of Medicine, 
Vol.352, No.11, pp.1103-1111 
[80] Willoughby, R.; Tieves, K.; Hoffman, G.; Ghanayem, N.; Amlie-Lefond, C.; Schwabe, 
M.; Chusid, M. & Rupprecht, C. (2005). Survival After Treatment of Rabies with 
Induction of Coma. The New England Journal of Medicine, Vol.352, No.24, 
pp.2508-2514 
[81] CDC (2004). Recovery of a Patient from Clinical Rabies — Wisconsin, 2004. Morbidity 
and Mortality Weekly Report, Vol.53, No.50, pp.1171-1173 
[82] Krebs, J.; Mandel, E.; Swerdlow, D.; Rupprecht, C. (2005). Rabies surveillance in the 
United States during 2004. Journal of the American Veterinary Medical Association. Vol. 
227, No. 12, (December 2005), pp.1912-1925 
[83] CDC (2006). Human Rabies — Mississippi, 2005. Morbidity and Mortality Weekly 
Report, Vol.55, No.8, pp.207-208 
[84] Blanton, J.; Hanlon, C.; Rupprecht, C. (2006). Rabies surveillance in the United States 
during 2006. Journal of the American Veterinary Medical Association. Vol. 231, No. 4, 
(August 2007), pp.540-556 
[85] Shah, U. (2007). Rabies Investigation & Response: A Multi-Disciplinary Approach, 
Proceedings of the 135th APHA Annual Meeting & Exposition, Washington, DC, 
USA, November 3-7, 2007 
[86] CDC (2007). Human Rabies — Indiana and California, 2006. Morbidity and Mortality 
Weekly Report, Vol.56, No.15, pp.361-365 
[87] CDC (2008). Human Rabies — Minnesota, 2007. Morbidity and Mortality Weekly 
Report, Vol.57, No.17, pp.460-462 
[88] CDC (2009). Imported Human Rabies — California, 2008. Morbidity and Mortality 
Weekly Report, Vol.5, No.26, pp.713-716 
[89] CDC (2009). Human Rabies — Missouri, 2008. Morbidity and Mortality Weekly Report, 
Vol.58, No.43, pp.1207-1209 
[90] CDC (2010). Presumptive Abortive Human Rabies — Texas, 2009. Morbidity and 
Mortality Weekly Report, Vol.59, No.7, pp.185-190 
[91] CDC (2010). Human Rabies — Kentucky/Indiana, 2009. Morbidity and Mortality 
Weekly Report, Vol.59, No.13, pp.393-396 
[92] CDC (2011). Human Rabies — Michigan, 2009. Morbidity and Mortality Weekly Report, 
Vol.60, No.14, pp.437-440 
 Non-Flavivirus Encephalitis 
 
278 
[93] CDC (2010). Human Rabies — Virginia, 2009. Morbidity and Mortality Weekly Report, 
Vol.59, No.38, pp.1236-1238 
[94] CDC (2011). Human Rabies from Exposure to a Vampire Bat — Louisiana, 2010. 
Morbidity and Mortality Weekly Report, Vol.60, No.31, pp.1050-1052 
[95] CDC (2011). Human Rabies — Wisconsin, 2010. Morbidity and Mortality Weekly 
Report, Vol.60, No.34, pp.1164-1166 
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
